06 September 2024
06 September 2024
Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.
On the last day of the European Society of Cardiology (ESC) 2024 Congress (2 September), a panel discussed the therapeutic potential with non-coding RNAs in cardiovascular disorders.
eGenesis conducted the first-in-human porcine kidney transplant earlier this year, though the patient died two months later.
Moderna is currently running a Phase I/II trial of the mRNA mpox vaccine mRNA-1769 in healthy participants.
A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.
The company has reduced its headcount by about 49% and suspended enrolment in a Phase II glioblastoma trial.
X-Chem's DEL technology allows for the simultaneous screening of billions of DNA-tagged compounds.
The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
